Product Information
LAMIVUDINE 10 MG/ML ORAL SOLN is a generic product labeled by Chartwell RX LLC, priced at $0.2176 per ML under NDC 62135070637. Its NADAC has been published 124 times since May 22, 2024.
FDA first approved this application on Oct 31, 2014. Its Orange Book therapeutic-equivalence code is AA.
Strength
10 mg/mL
Manufacturer
Chartwell RX LLCNDC
62135070637
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
7/22/2026
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA203564FDA Approved
10/31/2014
TE Code
AA
On Market Since
10/31/2014
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE 10 MG/ML ORAL SOLN has been published 124 times since May 22, 2024, and over the history we have for it it has declined 26.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2176 per ML |
|---|---|
| All-time high | $0.2955 (Jun 12, 2024) |
| All-time low | $0.2174 (Nov 20, 2024) |
| 52-week high | $0.2495 |
| 52-week low | $0.2176 |
| Median price | $0.2382 |
| Average price | $0.2420 |
| Largest weekly change | -14.7% (Nov 20, 2024) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lamivudine oral market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lamivudine oral market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE 10 MG/ML ORAL SOLN?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 10 MG/ML ORAL SOLN, manufactured by Chartwell RX LLC, is $0.2176 per ML (NDC 62135070637), effective Sep 30, 2026.
How has the price of LAMIVUDINE 10 MG/ML ORAL SOLN changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE 10 MG/ML ORAL SOLN has declined 26.3%. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE 10 MG/ML ORAL SOLN?
Since May 22, 2024, the NADAC for LAMIVUDINE 10 MG/ML ORAL SOLN has ranged from a low of $0.2174 (Nov 20, 2024) to a high of $0.2955 (Jun 12, 2024), with a median of $0.2382 per ML.
Are there cheaper alternatives to LAMIVUDINE 10 MG/ML ORAL SOLN?
No other NADAC-published product currently shares the active ingredient and strength of LAMIVUDINE 10 MG/ML ORAL SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LAMIVUDINE 10 MG/ML ORAL SOLN?
LAMIVUDINE 10 MG/ML ORAL SOLN (NDC 62135070637) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.